Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT03130244
Other study ID # GIW 16-001
Secondary ID
Status Active, not recruiting
Phase N/A
First received
Last updated
Start date September 23, 2019
Est. completion date March 30, 2025

Study information

Verified date December 2023
Source GI Windows, Inc.
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study will monitor changes in HbA1c for subjects in Intervention arm vs control arm.


Description:

Randomized, Single-Center, Parallel-group, Open-label Pilot Study to Evaluate the Safety and Effectiveness of the GI Windows Magnet Anastomosis System (MAS) When Used to Create a Dual-path Enteral Diversion Compared with Medical Therapy Alone To Effect Glycemic Control in Obese Patients with Type 2 Diabetes Mellitus (T2DM)


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 15
Est. completion date March 30, 2025
Est. primary completion date December 31, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Body mass index (BMI) 30 to 50. - Subject Type 2 Diabetes Criteria: 1. T2DM diagnosis =6 months but < 10 years 2. On 1 or more oral diabetes medications (with one at the minimum recommended therapeutic dose) 3. Hemoglobin A1C (HbA1c) between and including 6.5 and 10.0% (58 mmol/mol to 86 mmol/mol) at time of enrollment and has had a stable HbA1c over a 3-month period (i.e., <0.3% reduction) 4. Stable medication regimen (i.e., no change in diabetes medications) for at least 3 months prior to Screening Visit. - If subject has obesity-related comorbidities such as hypertension, dyslipidemia, and sleep apnea, these comorbidities must be well-controlled. - Able to understand and sign informed consent document - Has primary care physician and/or endocrinologist who follows patient for all comorbid conditions Exclusion Criteria: - Known or suspected allergy to nickel or titanium or Nitinol - Type 1 Diabetes - Use of injectable insulin - Uncontrolled T2DM Fasting glucose = 200 mg/dl (11.1 mmol/L) - Probable insulin production failure, defined as fasting serum C Peptide <1 ng/mL (0.3 nmol/l) - Any documented conditions for which endoscopy/colonoscopy would be contraindicated. - Contraindication to general anesthesia - Congenital or acquired anomalies of the GI tract, including atresias, stenosis or malrotation. - Any previous major surgery on the stomach (excluding sleeve gastrectomy), duodenum, hepatobiliary tree (excluding gallbladder), pancreas or right colon. - Previous technically difficult or failed colonoscopy or endoscopy - If on metformin, history of polycystic ovarian syndrome (PCOS) - Unable or unwilling to perform home blood glucose monitoring - History of or suspected gastrointestinal disease (e.g. cirrhosis, inflammatory bowel disease) - Diagnosis of active malignancy (i.e. not in remission) with the exception of squamous or basal cell carcinoma of the skin - Previous surgical or endoscopic treatment for obesity including but not restricted to intragastric balloons, endoscopic suturing or stapling procedures, malabsorptive sleeves. - Specific genetic or hormonal cause of obesity (e.g. Prader-Willi syndrome)

Study Design


Intervention

Device:
Magnet Anastomosis System
The MAS will be placed using an endoscope in the duodenum and and laparoscopically into ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the duodenum to ileum treats Type 2 diabetes.
Drug:
Best Medical Management
The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.

Locations

Country Name City State
Argentina Aleman Hospital Buenos Aires

Sponsors (1)

Lead Sponsor Collaborator
GI Windows, Inc.

Country where clinical trial is conducted

Argentina, 

Outcome

Type Measure Description Time frame Safety issue
Primary Mean change in HbA1c The primary effectiveness endpoint is Mean change in HbA1c from baseline 12 months
Secondary Mean change in Weight 12 month weight loss measured as a percent of total body weight loss and excess weight loss (using the BMI method) as well as weight/BMI change from baseline 12 months
Secondary Proportion of subjects achieving remission Proportion of subjects experiencing diabetes remission and/or partial remission at 12 months (as defined by the American Diabetes Association) 12 months
Secondary Mean change in diabetes medication Change in diabetes medication requirements from baseline to 12 months 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04243317 - Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults N/A
Recruiting NCT04101669 - EndoBarrier System Pivotal Trial(Rev E v2) N/A
Terminated NCT03772886 - Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball N/A
Completed NCT03640442 - Modified Ramped Position for Intubation of Obese Females. N/A
Completed NCT04506996 - Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2 N/A
Recruiting NCT06019832 - Analysis of Stem and Non-Stem Tibial Component N/A
Active, not recruiting NCT05891834 - Study of INV-202 in Patients With Obesity and Metabolic Syndrome Phase 2
Active, not recruiting NCT05275959 - Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI) N/A
Recruiting NCT04575194 - Study of the Cardiometabolic Effects of Obesity Pharmacotherapy Phase 4
Completed NCT04513769 - Nutritious Eating With Soul at Rare Variety Cafe N/A
Withdrawn NCT03042897 - Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer N/A
Completed NCT03644524 - Heat Therapy and Cardiometabolic Health in Obese Women N/A
Recruiting NCT05917873 - Metabolic Effects of Four-week Lactate-ketone Ester Supplementation N/A
Active, not recruiting NCT04353258 - Research Intervention to Support Healthy Eating and Exercise N/A
Completed NCT04507867 - Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III N/A
Recruiting NCT03227575 - Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control N/A
Completed NCT01870947 - Assisted Exercise in Obese Endometrial Cancer Patients N/A
Recruiting NCT05972564 - The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function Phase 1/Phase 2
Recruiting NCT06007404 - Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
Recruiting NCT05371496 - Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction Phase 2